Trial NCT03642132

View at ClinicalTrials.gov 
Org. Study IDs: B9991030
Secondary IDs: 2017-004456-30 B9991030 JAVELIN OVARIAN PARP 100

Last trial update was posted on 2023-04-06

MeSH Interventions

Avelumab Bevacizumab Talazoparib

MeSH Conditions

Carcinoma, Ovarian Epithelial Ovarian Neoplasms

Other Conditions

Ovarian Cancer

Stopping Reasons

Phase 3 B9991010 study was stopped due to futility of efficacy at interim analysis on 21Dec2018, and approvals of PARP inhibitors in front-line maintenance setting, Pfizer decided stopping enrollment in the B9991030 study on 19Mar2019.

Limitations And Caveats

As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study. A total of 104 participants were screened and 79 participants completed screening and randomized in the study before study discontinuation. As only 11% projected enrollment was met at the time of enrollment stop, the original study endpoints are no longer applicable and/or feasible; only the Safety, PK and Immunogenicity Analysis were done and these data are included in this report.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID